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Abstract
Background: Leishmania donovani (LD) is a protozoan parasite transmitted to humans from sand flies, which
causes Visceral Leishmaniasis (VL). Currently, the diagnosis is based on presence of the anti-LD antibodies and clinical
symptoms. Molecular diagnosis would require real-time PCR, which is not easy to implement at field settings. In this
study, we report on the development and testing of a recombinase polymerase amplification (RPA) assay for the
detection of LD.
Methods: A genomic DNA sample was applied to determine the assay analytical sensitivity. The cross-reactivity of the
assay was tested by DNA of Leishmania spp. and of pathogens considered for differential diagnosis. The clinical
performance of the assay was evaluated on LD positive and negative samples. All results were compared with
real-time PCR. To allow the use of the assay at field settings, a mobile suitcase laboratory (56 × 45.5 × 26.5 cm)
was developed and operated at the local hospital in Mymensingh, Bangladesh.
Results: The LD RPA assay detected equivalent to one LD genomic DNA. The assay was performed at constant
temperature (42 °C) in 15 min. The RPA assay also detected other Leishmania species (L. major, L. aethiopica and
L. infantum), but did not identify nucleic acid of other pathogens. Forty-eight samples from VL, asymptomatic
and post-kala-azar dermal leishmaniasis subjects were detected positive and 48 LD-negative samples were
negative by both LD RPA and real-time PCR assays, which indicates 100 % agreement. The suitcase laboratory
was successfully operated at the local hospital by using a solar-powered battery. DNA extraction was performed
by a novel magnetic bead based method (SpeedXtract), in which a simple fast lysis protocol was applied. Moreover, All
reagents were cold-chain independent.
Conclusions: The mobile suitcase laboratory using RPA is ideal for rapid sensitive and specific detection of LD especially
at low resource settings and could contribute to VL control and elimination programmes.
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Background
Leishmania donovani (LD) causes visceral leishmaniasis
(VL) in humans, kala-azar in the Indian Subcontinent
(ISC), where a VL elimination programme is underway
[1]. Individuals who have been infected through the bite
of a sand fly, harbor the parasite in mononuclear phago-
cytic cells and can remain asymptomatic for the rest of
their lives, or develop symptomatic VL. If left untreated,
VL could be lethal; after treatment, a proportion of sub-
jects develop a cutaneous form known as post-kala azar
dermal leishmaniasis (PKDL).
Diagnosis is currently based on the detection of anti-
Leishmania antibodies in subjects with clinical symp-
toms (persisting fever and splenomegaly). Serological
assays, e.g. direct agglutination test (DAT) and rK39 dip-
stick are widely used especially in poor resource settings.
DAT is sensitive and specific, but an 8-hour run-time,
low reproducibility and challenging quality control are
the main drawbacks [2, 3]. In contrast, the rK39 rapid
detection assay is very fast (15 min) and easy to use, but
its sensitivity and specificity varies [2–6]. In addition,
anti-leishmanial antibodies persist for a long time, there-
fore, current serological tests cannot be used for cure as-
sessment and diagnosis of VL relapse. However, high
anti-leishmanial antibody titre before treatment may be
useful for prediction of disease progression [7].
The VL elimination programme currently underway in
the ISC relies on identifying and treating VL as early
and efficiently as possible so as to reduce morbidity and
mortality and at the same time remove sources of further
transmission [1]. Detection of the parasite or parasite DNA
would greatly improve case management, disease control
as well as the investigation of transmission dynamics.
The presence of the parasite can be detected through
molecular diagnosis using the real-time polymerase
chain reaction (PCR), which is highly sensitive and spe-
cific [8–12] but unsuited for implementation at primary
and secondary health-care facilities. It must be operated in
a well-equipped laboratory by highly-trained personnel
and reagents must be kept at -20 °C [13].
A highly specific and sensitive test would be needed
to sustain the long-term current achievements of the
VL elimination programme in the ISC [14]. There is
therefore, a demand for a simple and rapid molecular
assay. The recombinase polymerase amplification (RPA)
assay is an isothermal amplification system [15]. The
amplification of the DNA in the RPA relies on enzymes
and proteins to replace the repetitive cycles of three
temperatures (94 °C, DNA denaturation; 50–60 °C, pri-
mer annealing; 72 °C extension) in the PCR. In con-
trast, the RPA reaction carries out at a constant
temperature (42 °C) and even using the body heat [16].
In addition, all reagents are cold chain independent and
can be kept at 38–40 °C ambient temperature for up to
three months without any effect on the assay perform-
ance [17–19].
In this study, RPA assay was developed for the detec-
tion of the LD and assay sensitivity, specificity and
cross-reactivity were studied. To facilitate the use of the
developed assay at point of need, two mobile suitcase
laboratories were developed. In addition, operational
feasibility of the suitcase laboratory using RPA and
SpeedXtract in the field was also explored.
Methods
Generation of the DNA LD molecular standard
A molecular DNA standard representing 1–310 nt of LD
kinetoplast minicircle DNA (kDNA, GenBank accession
number: Y11401.1) was synthesized and inserted into
pcDNA3.3-TOPO plasmid vector (GeneArt, Invitrogen,
Darmstadt, Germany). The plasmid was linearized with
BbSl restriction enzyme (New England Biolabs, Frankfurt
am Main, Germany). The number of DNA molecules per
microliter was measured by the Quant-iT™ PicoGreen®
dsDNA Assay Kit (Fisher Scientific GmbH, Schwerte,
Germany) and calculated with an equation as described
before [20]. A dilution range of 107–101 molecules/μl of
the molecular standard was produced to determine the
analytical sensitivity of LD RPA assay. The standard was
tested using a real-time PCR assay as described previously
[8] applying KAPA SYBR FAST ABI Prism kits (Peqlab,
Erlangen, Germany) and on the Stratagene Mx305P device
(Agilent, California, USA).
LD RPA assay primers and probe
To select the RPA primers and exo probe combination,
which produces the highest LD RPA assay analytical sensi-
tivity, eight forward primers (FPs), nine reverse primers
(RPs) and one exoprobe were tested (Additional file 1: Fig-
ure S1). All oligonucleotides were produced by TibMolBiol
(Berlin, Germany). The RPA assay was performed by using
the TwistAmp exo kits (TwistDx Cambridge, UK) as de-
scribed below.
Analytical sensitivity of the LD RPA assay
Concentrations between 107 and 101 molecules/μl of the
DNA molecular standard were used to determine the
analytical sensitivity of LD RPA assay in eight replicates.
In addition, culture promastigote DNA extracted with
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
was used to determine the analytical sensitivity of the RPA
assay. Considering 100 fg of culture DNA equivalents to
one parasite [21], analytical sensitivity was determined
from 100 to 1 parasite, where the volume of template
DNA in each reaction was 5 μl.
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Cross-reactivity, clinical sensitivity and specificity of the
LD RPA assay
DNA of pathogens listed in Table 2 were used to deter-
mine the assay cross-reactivity. Total of 48 archived DNA
samples from VL patients, asymptomatic individuals and
PKDL patients were tested by both RPA and real-time
PCR assays [22]. All VL patients (N = 23) were either para-
sitologically confirmed or diagnosed with VL in accordance
with Bangladeshi national guidelines [23]. Likewise, all
asymptomatic individuals (N = 5) were habitants of VL
endemic areas and clinically healthy but positive in
Leishmaniasis DAT and rK39 dipstick test. PKDL pa-
tients (N = 20) were rK39 test positive with previous
history of VL and negative for fungus and leprosy. To
determine the specificity of the assay, 48 archived DNA
samples including endemic healthy controls (N = 35),
non-endemic healthy controls (N = 5) and disease con-
trols (six malaria cases and two TB cases) were also in-
vestigated. QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) was used to extract DNA from Buffy
coat of VL patients, asymptomatic and control individ-
uals where QIAamp DNA mini kit was used for the
skin biopsy from PKDL patients. All VL, PKDL and
asymptomatic cases were positive for LD DNA by real-
time PCR, while controls (healthy and disease) were
negative for rK39, DAT and LD DNA by real-time PCR
as described below.
Real-time PCR for Leishmania
Quantitative detection of Leishmania DNA was performed
on a Biorad CFX96 icycler system using primers and
Taqman probe: 5′-GCG ACG TCC GTG GAA AGA A-3′,
5′-GGC GGG TAC ACA TTA GCA GAA-3′ and (FAM):
5′-CAA CGC GTA TTC CC-3′ (Applied Biosystems Inc.,
Foster City, CA, USA) targeting the repetitive sequence of
L. infantum Genome (77–142 nt of Genbank accession
number: L42486.1) by following a previous method [22].
Each reaction was run using a total of 11 μl of PCR mix
(Applied Biosystems Inc., Foster City, CA, USA) plus 9 μl
of extracted DNA (buffy coat or skin biopsy). Each sample
was run in duplicate. However, samples with very late amp-
lification (≥ 40 cycles) were repeated in triplicate.
Mobile suitcase laboratory
As described previously [18], two mobile suitcase labora-
tories (Fig. 1) were constructed to have separate work-
spaces for nucleic acid extraction and detection in order
to avoid any possible contamination. The main idea was
to use a water- and dust- resistance case, which was not
only employed to transport and store the equipment as
well as the reagents, but also to perform the test directly
in the suitcase. The mobile set up was powered by solar
panels and a power pack (Yeti 400 set, GOALZERO,
South Bluffdale, UT, USA). The fully charged battery
powers the two laboratories for up to 18 h.
In the extraction suitcase, a simple fast lysis protocol
(SpeedXtract, Qiagen, Hilden, Germany) was deployed
as follows: 500 μl of whole blood was incubated with
1500 μl of the enrichment buffer and 30 μl of the mag-
netic beads for 3 min at room temperature. The magnetic
beads were separated using a magnetic stand and then the
supernatant was removed without disturbing the beads.
Fig. 1 The mobile suitcase laboratories. The mobile set up was built to host all reagents and equipment to perform the SpeedXtract (left suitcase).
Another suitcase was used to perform the RPA assay (right suitcase). The extraction workplace includes in addition to the standard equipment, a heat
block and a magnetic stand, while the detection suitcase contains the tubescanner. The size of each suitcase is 56 × 45.5 × 26.5 cm. The bottom of the
suitcase was stuffed with foam cubes to absorb shocks. On the top of the foam, a PVC layer was fixed. This PVC layer contained cutouts to host the
equipment. All the edges around the equipment and the edges of the case on the PVC layer were glued with hot glue
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Then the beads were washed twice with 500 μl enrich-
ment buffer. Thereafter, 100 μl of the lysis buffer was
added and the mix was incubated at 95 °C for 10 min. The
beads were then separated and 5 μl of the supernatant was
used in the RPA reaction. The total time needed for the
extraction was 20 min.
In the detection suitcase, 5 μl of the RPA primers and
probe mix was added to the RPA lyophilized pellet
(TwistAmpexo kits, TwistDx, Cambridge, UK) at concen-
tration of 420 nM and 120 nM, respectively. Then 40 μl of
rehydration buffer containing 14 mM Mg acetate was
added. Finally, 5 μl of template was added. The tube was
closed and mixed well before it was placed into the tubes-
canner (Twista, TwistDx, Cambridge, UK) and incubated
for 15 min at 42 °C. The emitted fluorescence signals were
measured at 20 s intervals. A combined threshold and first
derivative analysis was used for signal interpretation.
The total time for RPA reaction including handling was
20 min.
Field feasibility evaluation of suitcase laboratory
Blood samples were collected from seven patients hospi-
talized at the Surya Kanta Kala-azar Research Center in
Mymensingh (Additional file 1: Figure S2). Nucleic acid
was extracted from whole blood using the SpeedXtrcat
method and RPA test was performed in the field as de-
scribed above. Concurrently, buffy coats were shipped to
the central diagnostic laboratory in the icddr, b, where
DNA was extracted from the buffy coat using the Qia-
gen DNA blood kit and real-time PCR was carried out
as described before [22].
Statistical methods
For the LD RPA assay analytical sensitivity using the
molecular DNA standard, a semi-log regression analysis
and a probit analysis were performed by plotting the
RPA threshold time against the number of molecules
detected using PRISM (Graphpad Software Inc., San
Diego, California) and STATISTICA (StatSoft, Hamburg,
Germany), respectively. Sensitivity and specificity were
calculated using standard formulas.
Ethical consideration
The study used archive samples, which were collected
through different previous studies with Principal Investi-
gator Dr. Dinesh Mondaland G. M. Khan (PR-13090,
PR-13045 and PR-09069). For use of archive samples for
eventual future activities on VL, consent from study par-
ticipants and approval from the Ethical Review Commit-
tee of the icddr, b had been obtained.
Results
The analytical sensitivity was determined using 10-fold di-
lution series of the synthetic molecular kDNA standard
(107–101 molecules/μl) and eight FPs, nine RPs and one
probe (Additional file 1: Figure S1). Only FP3 + RP3
(Table 1) were able to amplify down to 100 DNA mole-
cules/reaction (Fig. 2a), while the other combinations were
not successful.
The FP3 + RP3 were selected for further LD RPA assay
validation steps. Eight LD RPA assay runs on the 107–
101 dilutions of the molecular standard were performed.
The collected data were used in the semi regression and
the probit regression analyses. The LD RPA assay results
were reproducible in a maximum of 12 min (Fig. 2b).
The limit of detection probability in 95 % of cases was
39 DNA molecules (Fig. 2c). Moreover, The LD RPA
assay detected down to one LD genomic DNA (Fig. 3).
Standard genomes of LD, L. major, L. aethiopica and
L. infantum were positive in the RPA assay, while other
Leishmania species, parasites and bacteria were negative
(Table 2). The sensitivity of the LD RPA assay was esti-
mated using 48 samples from three different forms of
the LD infection: VL, asymptomatic and PKDL, whereas
another 48 negative control samples were used to deter-
mine the specificity of the assay (Table 3 and Additional
file 1: Table S1). All samples were tested simultaneously
with both LD RPA and real-time PCR assays. The LD
RPA assay correctly detected positive samples with 100 %
correspondence with the real-time PCR. Moreover, no
amplification was detected in the negative samples.
During the field assessment at Surya Kanta Kala-azar
Research Centre in Mymensingh (Additional file 1:
Figure S2), five samples were positive in both real-time
PCR and RPA, while two samples were negative (Additional
file 1: Table S2). Using suitcase laboratory, results were pro-
duced in 40 min, which included extraction and detection
procedures, whereas, real-time PCR was performed in 4 h
in a highly equipped laboratory in icddr, b, Dhaka.
Discussion
The LD RPA assay was designed to amplify 160 nt of the
kDNA gene, which is present in a high copy number in
LD (~10,000 DNA copies/cell) [24]. The LD RPA assay
detected down to 100 DNA copies applying the LD
DNA linearized plasmid (Fig. 2), and one LD genomic
DNA (Fig. 3). Using 96 buffy coats and skin biopsies col-
lected from VL, asymptomatic and PKDL cases as well as
Table 1 LD RPA primers and probe sequences
Name Sequence (5´-3´) Amplicon
length
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negative control, the LD RPA assays had the same clinical
sensitivity and specificity as the real-time PCR [22] (Table 3).
However, the RPA produced results six to nine times faster
than the real-time PCR, and does not require the same level
of equipment and training.
The most challenging step in the RPA assay develop-
ment is the design of a primer pair able to amplify a very
low DNA copy number [13, 17, 18, 25–28]. Neither a
program nor strict rules are available. In this study, 8
FPs and 9 RPs were chosen randomly around the exo
probe binding sites (Additional file 1: Figure S1). All oli-
gonucleotides combination failed to reach the needed
assay sensitivity except FP3 and RP3 (Table 1). The LD
RPA exo probe generating the highest fluorescence sig-
nal was placed in the same direction as the RP and has a
short 5′ end. The same model was successfully applied
in two studies [18, 25], but did not performed well in
others [13, 19].
The LD RPA assay did detect L. donovani and other
Leishmania spp. (L. major, L. aethiopica and L. infantum).
This is due to the fact that the RPA primers and probe are
able to amplify and detect target genes containing 5–9 mis-
matches [25, 29, 30]. A BLAST search revealed an identity
between 93 and 100 % of RPA FP3 and RP3 and 88–100 %
of the RPA exo probe to sequences of the above mentioned
Leishmania species (Additional file 1: Figure S3).
Recently, a RPA assay for the detection of canine VL
was developed [31]. The assay amplified both LD and L.
infantum. It deployed a lateral flow system to readout the
results with naked eyes, which tremendously decreases the
assay run costs. Nevertheless, this required additional steps
to transfer the amplified product to another tube for dilu-
tion and detection, which increased the possibility of cross-
contamination and the assay run time [32]. In contrast,
our approach depended on a probe system that allowed
the amplification and the detection in a single closed tube.
Several loop-mediated isothermal amplification (LAMP)
assays were established to identify the Leishmania para-
sites [33–38]. The LAMP results can be read by naked
eye, nevertheless, the LAMP assay requires six primers
and no probe system has yet been implemented. More-
over, LAMP produced results in 60 min [39]. In contrast,
the RPA assay was very fast (in a maximum of 15 min)
and utilized two primers and one probe.
The SpeedXtract represents a promising tool for the
nucleic acid extraction at point of need. First it allowed
the isolation of leukocytes from the whole blood in
3 min. Then a simple DNA extraction protocol combining
a lysis buffer and heat is applied. Moreover, the reagent is
stable at room temperature. The SpeedXtract without the
enrichment step was previously deployed for Ebola virus
RNA extraction [19]. To the best of our knowledge, this is
the first report on using it for a parasitic disease.
There are several reasons why we need a test that can
detect the presence of Leishmania parasites and can be
deployed widely in low-resource settings. Effective case
management requires a test that can diagnose VL among
Fig. 2 LD RPA assay analytical sensitivity. a Fluorescence development
in one RPA run by using 107–101 DNA molecules/reaction of the LD
DNA molecular standards (Graph generated by ESEquanttubescanner
studio software). The sensitivity was 100 DNA molecules. No fluorescence
was recorded between 3 and 4 min because a mixing step is necessary
to increase the assay sensitivity. b Reproducibility of LD RPA assay
using data sets of eight RPA assay runs using the DNA molecular
standards. LD RPA assay produced results between 3 and 12 min.
107–102 DNA molecules were detected 8 out of 8 runs. 101 copies
were not identified by the LD RPA assay. The error bars represent
the standard deviation. No error bars were shown for 106–104
because values were consistence at 5.7 min in all eight RPA runs.
c The probit regression analysis using data of eight RPA assay runs.
The limit of detection at 95 % probability (39 DNA molecules) is
depicted by a triangle
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other causes of illness (differential diagnosis) and assess
as early as possible whether treatment has succeeded or
failed (test-of-cure). Effective, sustainable VL control and
elimination requires a test that can identify subjects who
can transmit the infection as early as possible (even be-
fore they become symptomatic) to remove the source of
transmission [14]. Especially now that the prevalence of
the disease had dropped following the attack phase of
the VL elimination programme in the ISC. Such test
should be accurate, reproducible, inexpensive and user-
friendly.
The current study successfully explored that RPA
assay is feasible at field settings to detect leishmaniasis
using suitcase laboratory. The selection of suitcase la-
boratory provided the following advantages: (i) Easy to
carry, transport and ship; (ii) Power source from solar
panel with power pack; (iii) Easy to be implemented in
low resource settings; (iv) A magnetic bead extraction
was applied to avoid the creation of aerosols and the use
of a high-speed centrifuge; (v) All reagents are cold
chain independent; and (vi) A tightened waste container
was used, which was autoclaved or incinerated before
disposal to avoid contamination to the environment,
However, the current cost of the mobile suitcase labora-
tories and the solar power batteries is 8500 Euro and
cost per reaction is six euros inclusive of the controls
Fig. 3 Performance of LD RPA assay on culture promastigote DNA representing with 100 (red), 10 (blue) and 1 (green) LD cell. Limit of detection
was one LD cell. Orange is the negative control
Table 2 Cross-reactivity investigation for LD RPA assay
Pathogen name Number of isolates Sample type and reference test LD RPA assay results Source





L. major MHOM/IL/81/FEBNI 1 Positive
L. aethiopica MHOM/ET/72/L100Z14 1 Positive
L. infantum (50134D) MHOM/TN/80/IPT-1 1 Positive American Type Culture
Collection, Manassas, USA
L. tropica (50129D) 1 Negative
L. amazonensis 1 Negative Dept. of Microbiology,
University Medical Center
Gottingen, GermanyL. braziliensis 1 Negative
Toxoplasma gondii 1 Negative
Plasmodium falciparum 3 DNA extracted from blood
samples of malaria patients.
Plasmodium species-specific
nested PCR was performed [40].
Negative Icddr, b
Plasmodium vivax 3 Negative
Salmonella typhi 1 DNA extracted from culture Negative
Mycobacterium tuberculosis 2 DNA extracted from lymph
node aspirate from two extra
pulmonary TB patients.
Both were positive in culture
and IS6110 PCR [41].
Negative
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and the extraction. Lowering the cost will broaden its
application in the most affected countries. In addition
to diagnosis, integration of an internal positive control
and an algorithm for the quantification of number of
LD cells will maximize its use as test-of-cure during
post-treatment follow-up.
Conclusion
The use of a mobile suitcase laboratory is advantageous
for rapid, sensitive and specific detection of LD using
SpeedXtract and RPA assay, especially, at low resource
settings such as Bangladesh and could contribute to VL
control and elimination program. However, before its
recommendation for the program, further validation of
the LD-RPA assay incorporated in suitcase laboratory
through a prospective study is merited.
Additional file
Additional file 1: Figure S1. LD RPA primers and probe sequences
aligned with the LD amplicon. One RPA exo probes (P), 8 forward primers
(FPs) and 9 reverse primers (RPs) were tested to select combinations
yielding the highest analytical LD RPA sensitivity. Figure S2. Field exercise
in Mymensingh, Bangladesh. (A) The suitcase laboratory, where the nucleic
acid extraction using the SpeedXtract kit was performed in 20 min. (B) The
RPA assay was accomplished in another suitcase laboratory to avoid
cross-contamination. (C) The team while screening blood samples. (D)
The research team were able to operate the mobile laboratory during
a power cut in the hospital because the laboratory was powered by
the solar power pack. Figure S3. Mapping 100 sequences derived by
BLAST nucleotide search to the LD RPA amplicon as well as RPA
primers and probe. The Genbank accession number and the species
of Leishmania were given. Grey represents the identical sequence. A,
C, G, T were highlighted in red, violet, yellow, green, respectively,
whenever a mismatch to the LD RPA amplicon was recorded. DNA sequence
of L. donovani, L. infantum, L. major and L. chagasi were picked up by the
BLAST search but not other leishmania species or nucleotide sequence of
other pathogens. Table S1. Screening 48 samples with leishmania real-time
PCR and RPA assays. Table S2. Testing clinical samples from patient
hospitalized at the Surya Kanta Kala-azar Research Center in Mymensingh,
Bangladesh. (DOCX 12654 kb)
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